Cite

HARVARD Citation

    Buckley, H. et al. (n.d.). 73: Tyrosine kinase inhibitors (TKIs) as first-line treatment for advanced EGFR mutated non-small cell lung cancer (NSCLC): a single-centre experience. Lung cancer. pp. S35-. [Online]. 
  
Back to record